Directed molecular evolution of G protein-coupled receptors for stable and functional expression in Escherichia coli

G蛋白偶联受体的定向分子进化以在大肠杆菌中稳定和功能性表达

• 批准号: nhmrc : 520309
• 负责人: Dr Daniel Scott
• 金额: $ 25.57万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: Early Career Fellowships
• 财政年份: 2008
• 资助国家: 澳大利亚
• 起止时间: 2008-01-01 至 2013-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/directed-molecular-evolution-escherichia-coli/115779
• 关键词: Directed; molecular; evolution; protein; coupled

Approximately half of all prescription drugs on the market act on G protein coupled receptors (GPCRs). The mechanisms underlying GPCR function are mainly unknown due to a lack of structural information. No solved structures exist for any of the estimated 800 human GPCRs, making it difficult to design new drugs. By applying advanced protein engineering techniques I aim to produce human GPCRs in bacteria to ultimately acquire structural information, which will enable novel drug development.

市场上大约一半的处方药作用于G蛋白偶联受体（GPCR）。由于缺乏结构信息，GPCR功能的潜在机制主要是未知的。在估计的800种人类GPCR中，没有任何一种存在已解决的结构，这使得设计新药变得困难。通过应用先进的蛋白质工程技术，我的目标是在细菌中产生人类GPCR，最终获得结构信息，这将使新药开发成为可能。